David Bajor is an Oncology physician affiliated with University Hospitals Cleveland Medical Center. OpenAlex indexes 298 publications with 4,665 citations (h-index 24); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
11100 Euclid Ave
Cleveland, OH 441061716
Telephone
216-844-3951Provider last certified this registry record 7 Dec 2020.
Clinical trials
- Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
Sponsor: Case Comprehensive Cancer Center
- CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer
Sponsor: David Bajor, MD
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year20253 payments
- Exelixis Inc.Program year20251 payment
- PFIZER INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
44.7%Serotonin-3 Receptor Antagonist13.2%Ondansetron Hcl100%Part D≥52 patientsAntidiarrheal microorganisms8.2%Creon100%Part D≥17 patients+ 5 more classes in this area
Nervous system
29.2%Phenothiazine8.3%Prochlorperazine Maleate100%Part D≥41 patientsOpioid Agonist8.1%Oxycodone Hcl63%Tramadol Hcl38%Part D≥24 patients+ 4 more classes in this area
Cardiovascular
11.7%Loop diuretic4.6%Furosemide100%Part D≥17 patientsAldosterone antagonist (MRA)3.2%Spironolactone100%Part D≥13 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Neutrophil extracellular traps induced by chemotherapy inhibit tumor growth in murine models of colorectal cancer
Journal of Clinical Investigation
2024 - Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Joseph Calabrese, MD
University Hospitals Cleveland Medical Center
Joseph Sabik, MD
University Hospitals Cleveland Medical Center
Amitabh Chak, MD
University Hospitals Cleveland Medical Center
Keming Gao, MD
University Hospitals Cleveland Medical Center
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”